Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$7.35 - $10.63 $2,675 - $3,869
-364 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$4.52 - $7.8 $781 - $1,349
-173 Reduced 32.22%
364 $2,000
Q2 2020

Aug 11, 2020

BUY
$21.21 - $31.55 $11,389 - $16,942
537 New
537 $15,000

Others Institutions Holding TCDA

About Tricida, Inc.


  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.